Table 5 Association between the distribution of TAB2 rs652921 genotypes and patient’s characteristics
Characteristics | Genotype | OR (95% CI) a | ||||
|---|---|---|---|---|---|---|
TT | TC | CC | Dominant (TT vs. TC/CC) | Recessive (TT/TC vs. CC) | Over-dominant (TT/CC vs. TC) | |
Age | ||||||
<43 | 14 (22.9%) | 30 (49.2%) | 17 (27.9%) | 0.54 0.77 (0.34–1.76) | 0.72 0.85 (0.36–2.04) | 0.80 0.91 (0.43–1.91) |
≥43 | 19 (27.5%) | 34 (49.3%) | 16 (23.2%) | |||
FIGO Stage | ||||||
Stage I | 15 (23.8%) | 29 (46.0%) | 19 (30.2%) | 0.77 0.87 (0.33–2.26) | 0.005 0.20 (0.06–0.67) | 0.04 2.46 (1.00-6.05) |
Stage II-III | 18 (26.9%) | 35 (52.2%) | 14 (20.9%) | |||
Pathological type | ||||||
Squamous | 28 (25.0%) | 56 (50.0%) | 28 (25.0%) | 0.96 0.97 (0.29–3.29) | 0.71 1.28 (0.35–4.77) | 0.72 0.81 (0.26–2.54) |
Others | 5 (27.8%) | 8 (44.4%) | 5 (27.8%) | |||
Tumor differentiation | ||||||
Low | 24 (24.7%) | 46 (47.4%) | 27 (27.8%) | 0.80 0.88 (0.34–2.33) | 0.32 0.57 (0.19–1.74) | 0.54 1.32 (0.54–3.21) |
Mod-High | 9 (27.3%) | 18 (54.5%) | 6 (18.2%) | |||
Lymph node involvement | ||||||
Positive | 7 (25.9%) | 8 (29.6%) | 12 (44.4%) | 0.80 0.85 (0.25–2.86) | 0.004 0.14 (0.03–0.59) | 0.03 3.52 (1.12–11.07) |
Negative | 26 (25.2%) | 56 (54.4%) | 21 (20.4%) | |||
Myometrial invasion | ||||||
>1/2 | 19 (26.0%) | 37 (50.7%) | 17 (23.3%) | 0.96 1.02 (0.41–2.54) | 0.20 1.95 (0.69–5.52) | 0.32 0.66 (0.29–1.50) |
≤1/2 | 14 (24.6%) | 27 (47.4%) | 16 (28.1%) | |||
Peritumoral intravascular cancer emboli | ||||||
Positive | 13 (26.0%) | 21 (42.0%) | 16 (32.0%) | 0.91 1.05 (0.42–2.66) | 0.45 0.67 (0.24–1.90) | 0.47 1.38 (0.58–3.26) |
Negative | 20 (25.0%) | 43 (53.8%) | 17 (21.2%) | |||
Involve others | ||||||
Positive | 11 (23.9%) | 22 (47.8%) | 13 (28.3%) | 0.61 | 0.34 | 0.73 |
Negative | 22 (26.2%) | 42 (50.0%) | 20 (23.8%) | 0.79 (0.31–1.97) | 0.62 (0.23–1.64) | 1.15 (0.50–2.63) |